Press Releases

Date Title and Summary Additional Formats
Toggle Summary Colin McCracken Joins Fluidigm as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019 , under
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 million Including equity offering, ending cash of $95.4 million SOUTH SAN FRANCISCO, Calif. , Feb.
View HTML
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ: FLDM) and Indica Labs, Inc. , today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry ™ (IMC ™ ).
View HTML
Toggle Summary Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases
Gaining insights into inflammatory bowel disease through mass cytometry and Imaging Mass Cytometry analysis of the human mucosal immune system Research aimed at more precise treatments for IMIDs using existing therapies and identification of new targets for drug development SOUTH SAN FRANCISCO,
View HTML
Toggle Summary Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
First commercially available, automated single-cell analysis application to enable co-detection of cellular protein and RNA expression using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), a leader in mass cytometry and
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 , after the close of
View HTML
Toggle Summary Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
View HTML
Toggle Summary Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.
View HTML